CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited is excited to announce that their new Palbociclib Tablets for breast cancer treatment have received drug registration approval in China. These tablets are designed to inhibit key enzymes and can be taken without food, avoiding interactions with other drugs. This milestone is expected to enhance the company’s range of cancer therapies.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
